Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Memory Pharmaceuticals Corp.

Division of Roche
www.memorypharma.com

Latest From Memory Pharmaceuticals Corp.

Stockwatch: Pain in the middle eight

In popular music parlance, the middle eight is the part of a song that is not a chorus or a verse. In America, it's called the bridge, although it can also be thought of as either the padding or less memorable parts of a music track. If life science companies were to be classified as either chorus, verse or middle eight companies, profitable biotechnology companies like Gilead Sciences and Celgene (which we own), that have attained the size that means they may never be acquired, would be the verses, while the chorus would include those companies like Regeneron Pharmaceuticals (which we own) and Alexion Pharmaceuticals that have easily surpassed profitability, but are not yet so big that they could never be acquired.

Neurology Companies

STOCKWATCH: Rotten vegetables for biotech's bad actors

The stock market is theater, a company's public show watched daily by churning audiences of thousands, some first-time punters, some gnarly hecklers. For investors, all corporations are merely players, each with their exits and their entrances. And once a quarter, each company takes a curtain call, acknowledging its owner-audience in a ritualized show of humility and subservience.

Metabolic Disorders Infectious Diseases

Stockwatch: Bitter-sweet biotech buy-outs

Speculation that the board of Amylin Pharmaceuticals recently rejected a $3.5 billion unsolicited acquisition offer from Bristol Myers Squibb (BMS) (scripintelligence.com, 29 March 2012) is both logical and fits the profile of one of the many bitter-sweet biotech buy-outs.

Metabolic Disorders Orthopedics

Stockwatch: Headaches in neuroscience

It has not been a good few months in the neuroscience therapeutic space and last week, in particular, saw the FDA reject one drug, and a clinical trial failure of another. GlaxoSmithKline set the stage for this theme last year when it announced its withdrawal from developing some neuroscience drugs; a shift in heritage for GSK as neuroscience was the therapeutic category that brought the company the blockbuster anti-depressant Seroxat/Paxil.

Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • Vaughn M Kailian, Interim Pres. & CEO
    Michael P Smith, CFO
  • Contact Info
  • Memory Pharmaceuticals Corp.
    Phone: (201) 802-7100
    100 Philips Pkwy.
    Montvale, NJ 07645
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register